Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06688045 · ClinicalTrials.gov registry record · Phase 1
A Study of the Effects of Itraconazole on the Plasma Levels of Nemtabrutinib (MK-1026-013)
A Phase 1 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT06688045 is a Phase 1 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 15 participants.
The verdict
NCT06688045, a Phase 1 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The goal of this study is to learn what happens to levels of nemtabrutinib in a person's body over time. Researchers will compare what happens to nemtabrutinib in the body when it is given with or without another medicine called itraconazole.
Interventions
- DRUG Nemtabrutinib
- DRUG Itraconazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2023-10-30 |
| Est. Completion | 2024-01-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06688045
The ClinicalTrials.gov registry entry for NCT06688045 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nemtabrutinib is the first listed.
NCT06688045 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06688045 about?
NCT06688045 is a clinical study titled "A Study of the Effects of Itraconazole on the Plasma Levels of Nemtabrutinib (MK-1026-013)". The goal of this study is to learn what happens to levels of nemtabrutinib in a person's body over time. Researchers will compare what happens to nemtabrutinib in the body when it is given with or without another medicine called itraconazole.
What is the current status of trial NCT06688045?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2023-10-30. Estimated completion is 2024-01-06.
What interventions are being tested in trial NCT06688045?
The interventions under investigation include: Nemtabrutinib (DRUG), Itraconazole (DRUG).
Who is sponsoring clinical trial NCT06688045?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.